Analytical Procedure Lifecycle Approaches in Accordance With ICH Q14 and ICH Q2(R2): Opportunity Knocks or Just Another Challenge and Headache? (Part 2)

There has been a significant transformation in the way pharmaceutical analytical procedures are developed, validated, and maintained. This shift was largely driven by the new ICH Q14 Analytical Procedure Development guideline¹ and the recently revised ICH Q2(R2) Validation of Analytical Procedures guideline,² along with USP chapters, such as <1220>,³ which emphasize a lifecycle and risk-based approach to ensure the quality of pharmaceutical products and the reliability and robustness of their associated analytical procedures, thereby moving beyond the traditional view of a method as a fixed set of conditions followed by a one-off validation. Instead, methods are increasingly being treated as evolving assets: designed with their intended purpose in mind, challenged systematically from a scientific risk perspective, transferred with greater understanding, and monitored throughout routine use.^1-7

Analytical quality by design (AQbD) is reshaping method development by placing the analytical target profile (ATP), risk assessment, knowledge management, and performance monitoring at the center of method design. Rather than relying on trial-and-error or one-factor-at-a-time (OFAT) studies, design of experiments (DOE) and predictive modeling have been explored to design optimal method conditions and to assess robustness supporting the definition of the method operable design regions (MODRs), along with suitable control strategies, consequently allowing for more flexible change management later in the lifecycle. The ICH Q14 lifecycle framework and its linkages to ICH Q2 and USP chapters are shown in Figure 1.

ICH Q14 and Q2(R2) Mark a Shift Toward More Strategic Risk-Based Decision-Making. What Are the Key Opportunities Associated With Adopting Risk-Based Analytical Lifecycle Procedure Approaches?

The ICH Q14 and revised ICH Q2(R2) frameworks provide a solid foundation for knowledge and quality risk management, where analytical risk evaluations inform method design, control strategy development, and change management.⁶ The introduction of minimal and enhanced development approaches allows flexibility based on risk and method complexity. Minimal approaches typically rely on traditional practices, often using univariate procedure development strategies such as OFAT. In contrast, enhanced approaches apply systematic, multivariate tools to support comprehensive, science-based risk assessments, a deeper understanding of variability sources, and the optimization of procedure performance (Table 1). This enables the identification of critical analytical procedure parameters and the assessment of their influence on performance, allowing scientists to gain insights that help minimize variability at its source rather than relying solely on downstream controls. This, in turn, supports the design of an effective control strategy, incorporating elements such as appropriate system suitability tests (SSTs) and sample suitability assessments (SSAs) to ensure consistent and reliable routine performance.

Although a minimal approach may suffice for low-risk, well-understood procedures, more complex or higher-risk methods are better addressed using an enhanced approach to ensure they are fit for the intended purpose. Enhanced approaches often use DOE, predictive modeling, and other risk assessment tools (e.g., those outlined in ICH Q9)⁷ to characterize a broader knowledge space related to procedure performance, supporting the definition of optimal analytical conditions and expanding robustness assessment capabilities. They support the establishment of a MODR and proven acceptable ranges (PARs), and they develop more robust control strategies, including SSTs and performance parameters monitored during stage 3. Such robustness assessments deepen knowledge of procedure capabilities, reduce the risk of out-of-specification results, and enhance confidence in both regulatory submissions and lifecycle management. Concepts such as MODRs and PARs also provide valuable flexibility for continuous improvement. Adjustments made within a validated MODR can typically be implemented post-approval without requiring additional regulatory submissions. By applying statistical tools, scientists can gain deeper insights into what drives method performance and enhances robustness. A few examples include DOE followed by analysis of variance to evaluate the significance of individual factors and their interactions, providing additional insights into the relationship between analytical response and analytical parameters. Response surface methodologies, including the generation of contour plots, further expand process understanding. Monte Carlo simulations or the calculation of prediction intervals enhance robustness assessment, while process capability analysis assesses the method’s ability to meet predefined specifications. Additionally, hybrid and mechanistic predictive models can be used to characterize complex relationships between analytical variables and responses. For example, gradient modeling in liquid chromatography enables the prediction and optimization of retention behavior across various gradient slopes and profiles. Similarly, mass transfer and kinetic models can simulate column performance and retention behavior under varying conditions such as flow rate and temperature. DOE-derived models are also powerful tools for method optimization and can be applied across a range of techniques, including the optimization of sample preparation protocols. These modeling approaches support more robust method development and also facilitate knowledge transfer, reduce experimental burden, and enable a deeper understanding of method dynamics across the lifecycle. Applying several of these tools can be perceived as challenging by scientists, often requiring specialized software or in-house-built predictive models to facilitate their implementation. Therefore, it is essential to adequately train scientists to use these tools to guarantee the accuracy of predictions and correctly interpret data. Building a toolbox for enhanced data processing and statistical competency within analytical teams will be critical to ensure that the outputs of these models meaningfully support risk assessment, method understanding, and decision-making. This does not need to be overwhelming: Starting with basic tools such as DOE-derived screening and optimization models, prediction models (often offered by several software vendors), and simple risk assessment tools such as heat maps and cause-and-effect diagrams can provide valuable insights into method performance and variability. With time, teams can progressively build competence and confidence by exploring more advanced techniques, supported by intuitive software platforms and collaborative learning. The key is to take the first step, recognizing that even small, incremental applications of statistical thinking can significantly enhance analytical understanding and decision-making.

Furthermore, ICH Q14 stresses the importance of structured documentation of method development strategy, experimental outcomes, and risk assessments in a way that ensures long-term usability, supports validation, and contributes to a reusable knowledge base. This approach facilitates effective knowledge management and enhances data transparency, traceability, and reusability—factors that are particularly valuable when leveraging prior knowledge or platform methods.

Analytical procedures are positioned as integral components of the overall product control strategy and are expected to be aligned with critical quality attributes and clinical relevance, particularly in the context of patient-centric specifications. They support product and process understanding, enable real-time release testing where applicable, and ensure consistent product quality. ICH Q14 promotes structured bridging strategies that facilitate performance-based post-approval changes, reducing regulatory burden while maintaining control. A key regulatory expectation is the clear identification, definition, and justification of established conditions (ECs) for analytical procedures through the ATP and risk-based development. ECs represent the legally binding elements of the ICH Q14 control strategy that, once approved, require regulatory notification or approval if changed. By distinguishing between critical and noncritical method parameters, organizations can propose ECs that are scientifically justified and aligned with the method’s intended use. This enables a more flexible and efficient approach to post-approval changes, where modifications within ECs can be managed under the pharmaceutical quality system, whereas changes outside ECs are subject to regulatory oversight. ECs are expected to be defined based on method performance data, product understanding, and risk assessment, ensuring that any change does not compromise the method’s ability to support product quality and patient safety.

What Are the Main Barriers to the Implementation of AQbD Principles?

The primary barrier is the organizational shift required in mindset, culture, and operational practices. Organizations must move from a traditional, compliance-driven validation mindset to one focused on scientific understanding and lifecycle management. Validation is no longer a single snapshot but an ongoing commitment to continuous monitoring and improvement. This shift demands technical training and cultural change across analytical scientists, quality control/quality assurance, regulatory affairs, and leadership. The goal is to embed robust scientific approaches and knowledge throughout the entire analytical lifecycle, reducing the risk of method failures over time. Ironically, these challenges stem from the very opportunity AQbD presents: the change of mindset when developing and assessing the performance of analytical procedures. One such challenge is misunderstanding the flexibility in ICH Q14, which allows both “minimal” (traditional) and “enhanced” approaches. Many organizations unfamiliar with AQbD default to the minimal approach, limiting their ability to build deeper knowledge, establish robust control strategies, and effectively manage risk—the true benefits of AQbD. The choice should be based on intended use, complexity, and risk to product—­not convenience or perceived regulatory preference. Emphasizing the ATP during procedure development and validation helps ensure fitness for purpose and supports ongoing performance monitoring during routine use. A scientifically sound approach integrates ATP, uncertainty evaluation, and long-term precision assessment, resulting in a more proactive and informed analytical strategy. It is worth noting that organizations can adopt a phased approach to implementation, gradually introducing AQbD elements as capabilities mature.

Resource demands and expertise gaps are also important barriers. Leveraging risk-based approaches requires balancing the benefits of obtaining high-quality information and associated post-approval flexibility vs. the required resource investment for implementation of the additional elements. Over time, the proposed strategy should streamline analytical procedure development, result in well-understood analytical procedures, and simplify their lifecycle management. Enhanced approaches are often perceived to require more upfront investment in terms of time, resources, and technical capabilities. Expertise in DOE, multivariate modeling, and risk-based control strategy design is still developing within many organizations. The lack of in-house statisticians or chemometricians can further discourage adoption. There are concerns that AQbD implementation leads to longer development timelines and higher resource use, but this overlooks the long-term benefits of thorough risk assessment and the use of multivariate tools. Enhanced approaches can lead to more efficient development and reduced downstream risk.

Both the minimal and enhanced approaches require (1) risk assessment, (2) identification of parameter set points and/or ranges, and (3) definition of an analytical procedure control strategy. The enhanced approach emphasizes application of more comprehensive and systematic risk assessment throughout the development process, often leveraging multivariate tools (e.g., DOE-derived models, chemometric models) to identify critical parameters, study factor interactions, and define performance-based control strategies. This results in a broader and deeper knowledge base to support robust procedure design.

In contrast, the minimal approach typically uses an OFAT strategy, ignoring possible interactions between factors and limiting information to support simultaneous changes of factors (joint effects), and it may fall short in controlling sources of variability. Additionally, identifying the optimal conditions can be challenging when using OFAT, as considerable effort is often spent exploring regions far from the true optimum (Figure 2).

The multivariate approach considers the joint effects and possible interactions, providing comprehensive information on how the variables influence method performance within the method's design space, and enables the identification of optimum performance regions and definition of the MODR. Often, multivariate approaches are perceived as requiring a much larger number of experiments than the OFAT approach. In practice, however, this is rarely the case. For example, consider a study with four factors, each assessed with five values (Figure 3). An OFAT approach would require 4 x 5 = 20 univariate experiments. In contrast, a multivariate design would require 29 (central composite design) or 21 (Doehlert design) different experiments. Although the number of experiments remains similar, the amount of information obtained is substantially greater, including estimates of main effects of the factors, interaction effects, and their joint effects, allowing for the definition of the MODR.

In practice, method development is often initiated using screening designs as a first step in the experimental strategy. These designs allow the evaluation of a wider range of factors and factor ranges while keeping the number of experiments relatively low, using efficient DOE structures such as Plackett-Burman or Optimal designs. Screening studies are particularly useful to identify the most influential (critical) factors affecting method performance, which can then be carried forward into subsequent optimization studies. This sequential strategy enables a more efficient allocation of experimental effort, focusing detailed multivariate optimization on the most relevant variables and thereby reducing the overall experimental burden while improving method understanding.

A minimal approach often suffices for low-risk procedures, especially when platform technology or existing procedures for similar products are available. However, the extent of the risk assessment should be guided by the procedure’s intended use, its complexity, and the associated risks to product quality. A strong statistical understanding and cross-functional collaboration are key to effectively applying the principles of Q2 and Q14, as these are not yet standard practice. Below are several examples of how statistical tools can support implementation:

• Definition of a maximum allowed measurement uncertainty (target measurement uncertainty) as ATP criteria, usually derived from the product specification.
• Integration of statistical tools during procedure development (stage 1) to enhance robustness assessment (e.g., Monte-Carlo simulation and prediction intervals), supporting the establishment of the MODR and meaningful analytical control strategies.
• Use of multivariate tools (e.g., DOE and predictive modeling) to expand the knowledge space and inform validation strategies that confirm model suitability.
• Use of residuals analysis during calibration function assessment to compare linear and nonlinear, or back-calculated concentration residuals and calibration models.
• Implementation of measurement uncertainty estimation strategies during stage 2 (procedure validation), such as calculating the repeatability/intermediate precision variance confidence intervals, or prediction/tolerance intervals for combined accuracy and precision assessment and comparing them to predefined acceptance criteria. Note that ICH Q2(R2) does not explicitly address acceptance criteria, clearly define the role of the ATP in procedure validation, explain how to assess the reportable value precision, and define the procedure replication strategy.
• Use of trending tools during stage 3 to verify ongoing procedure performance and assess long-term precision.

Although these tools and features are familiar to statisticians and executable in general-purpose statistical software, many analysts may prefer to use dedicated software packages for analytical method lifecycle statistical assessment. Currently, no single commercial tool covers the full end-to-end analytical procedure lifecycle management. Some packages offer chromatographic method development and robustness tools; others start at the robustness study level and run through the analytical procedure lifecycle, right through to validation and evaluation of the replication strategy, and even to performance monitoring and analytical procedure transfer assessment.

Coming Up…

The next article in this series will continue to explore industrial perspectives on the opportunities and challenges associated with analytical procedure lifecycle guidelines, including the main challenges to the implementation of AQbD principles. Could the perceived complexity of the framework introduced in ICH Q14 discourage the industry from fully implementing it? Is it necessary to adopt the full framework all at once to benefit from the enhanced approach? Are there concerns around how regulators will interpret and apply Q2(R2) and Q14?

References

1. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Harmonised Guideline Q14: Analytical Procedure Development; ICH: Geneva, Switzerland, 2023.
2. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Harmonised Guideline Q2(R2): Validation of Analytical Procedures; ICH: Geneva, Switzerland, 2023.
3. United States Pharmacopeia. General Chapter <1220> Analytical Procedure Life Cycle. In USP–NF; United States Pharmacopeial Convention: Rockville, MD, 2022.
4. United States Pharmacopeia. General Chapter <1225> Validation of Analytical Procedures (draft). Pharmacopeial Forum 2025, 51 (6).
5. United States Pharmacopeia. General Chapter <1221> Ongoing Procedure Performance Verification (draft). Pharmacopeial Forum 2025, 51 (4).
6. Guiraldelli Mahr, A.; Roussel, J.-M.; Flores Ortiz, L.; Clarke, A. Analytical Procedure Lifecycle Approaches in Accordance with ICH Q14 and ICH Q2(R2): Opportunity Knocks or Just Another Challenge and Headache? (Part 1). LCGC Int. 2026, 3 (3), 24-28.
7. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline Q9: Quality Risk Management; ICH: Geneva, Switzerland, 2005.